Ravinder Singh and Vaibhavi Sonetha, PhDAIMimicking human vision: The new standard for medical image fidelityRavinder Singh and Vaibhavi Sonetha, PhD, of Citius Healthcare Consulting, discuss a new method for assessing medical image fidelity.April 11, 2025Page 1 of 1Top StoriesMolecular ImagingSPECT/CT MPI may guide medical therapy in CAD patientsSPECT/CT myocardial perfusion imaging can identify patients with coronary artery disease who are more likely to benefit from specific therapies.MRIAI model uses MRI data to predict brain cancer patient survivalWomens ImagingUltrafast breast MRI's advantages may need to be reconsideredMolecular ImagingPET/MRI and DECT show abnormalities in long COVID patientsUltrasoundARRS: Cancer status should be considered for axillary breast ultrasound
![Images depict axial MRI scans in a 50-year-old premenopausal female patient with biopsy-proven 12-mm invasive lobular cancer in the lower outer quadrant of the left breast. Upper images are subtracted dynamic contrast-enhanced (DCE) MRI scans from the first and second postcontrast acquisitions. Lower images are ultrafast MRI scans obtained within 24 hours after the DCE study (four consecutive subtracted dynamic frames from time points [T] 6–9). There is marked background parenchymal enhancement (BPE) on the DCE MRI scans. Thus, the known cancer (arrow) is barely visible; it exhibits only slightly stronger enhancement than the normal fibroglandular tissue, which results in low conspicuity. At ultrafast MRI there is less BPE, and still the cancer is barely visible because it starts to enhance simultaneously with the BPE. The conspicuity of the cancer is even reduced compared with the DCE series. Both of the readers missed this cancer on both the DCE and ultrafast MRI scans.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2025/05/2025-05-06-rsna-ultrafast-dce-mri-breast.Gzvq76udFr.jpg?auto=format%2Ccompress&fit=crop&h=167&q=70&w=250)
